10-Q · May 14, 2026
Nexentis Technologies reported a significant increase in net loss from continuing operations of $7,447,000 for the three months ended March 31, 2026, compared to $1,116,000 in the prior year, primarily due to a $6.3…
Earnings analysis · 10-Q
NXTS earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted portion of Nexentis Technologies’ June 30, 2026 10-Q does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so current-period financial trends cannot be assessed.…
Read full summary
The extracted portion of Nexentis Technologies’ June 30, 2026 10-Q does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so current-period financial trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and stated that incorporating MitoCareX into the control environment did not materially affect internal controls. No quantitative guidance was provided, and the company did not provide Item 1A risk-factor disclosures because it qualifies as a smaller reporting company.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Deemed Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, according to the filing.
-
MitoCareX Controls Integration
Following the acquisition of MitoCareX, the company included the business within its existing financial reporting and consolidation controls; management stated the inclusion did not materially affect internal controls.
What to watch
-
Risk-Factor Disclosure Omitted
The company stated in Item 1A that, as a smaller reporting company under Rule 12b-2, it is not required to provide risk-factor disclosures; therefore, this filing provides no updated quantitative risk-factor detail.
-
Post-Acquisition Integration
The MitoCareX acquisition required integration into existing financial reporting and consolidation controls during the period ended June 30, 2026. Although management reported no material control impact, post-acquisition integration remains an execution consideration.
Management's outlook
No quantitative guidance or outlook was provided in the extracted 10-Q text.
Earlier filings 4
10-K · March 31, 2026
Nexentis completed a strategic re‑orientation during/after the 2025 year: it closed the acquisition of MitoCareX (closed October 20, 2025) making MitoCareX a wholly‑owned subsidiary (100% of fully‑diluted share capital)…
10-Q · May 15, 2025
Q1 2025 showed early commercial traction: revenue rose to $66,000 from $44,000 year‑over‑year and gross profit expanded to $52,000. Operating loss narrowed to $(619,000) versus $(899,000) in Q1 2024, but net loss…
10-Q · August 14, 2024
N2OFF reported six‑month revenue of $60,377 (H1 2023: $157,618) and a H1 net loss attributable to stockholders of $1,557,012 (H1 2023: $2,423,183). Cash and cash equivalents were $4,467,529 at June 30, 2024 and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.